[Qiltrack AI] Greenwich Lifesciences Inc (GLSI) 3-Minute Overview

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Greenwich Lifesciences Inc (GLSI) 3-Minute Overview > **💡 One-Sentence Summary** > > Greenwich Lifesciences is a tiny, clinical-stage biotech that’s basically a one-drug bet on GLSI-100, an immunotherapy aiming to prevent breast cancer from coming back, now in a Phase III trial. > **📍 Basic Profile** > > Market Cap **$0.3 billion** · Biotechnology · NASDAQ · Price **$22.30** --- > **⚡ 3 Things You Should Know** > > 1. 🎯 **Single-asset, late-stage bet:** The whole story is GLSI-100 (breast cancer recurrence prevention) in the Phase III FLAMINGO‑01 trial; success could be transformational, but failure would wipe out most of the equity story. > > 2. 🧪 **Promising but early efficacy signal:** Management just reported an ~80% reduction in recurrence in one open-label arm of FLAMINGO‑01, which is very encouraging—but it’s preliminary and not from the main double-blind portion that will actually drive approval. > > 3. 💸 **High-risk valuation + dilution overhang:** There’s no revenue, very negative returns on equity, and cash burn funded by shareholders; with a ~58x price-to-book and small-cap size, the stock already prices in a meaningful chance of success and will likely require more equity raises along the way. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Loss-making clinical-stage biotech; ROE about **-1,000%** driven by small equity base and ongoing R&D spend, no commercial revenue yet | > | Growth Rate | Steady📈 (for a pre‑revenue biotech) | Pipeline progress is growing (Phase III enrollment, new data), but **revenue growth = N/A** since there are no product sales | > | Financial Health | Healthy💚 (for now) | **Debt-to-equity 0%**, current ratio ~**2.3x**, quick ratio ~**2.6x** → no debt and decent liquidity, but cash flow per share is **negative** | > | Valuation | Expensive | **PE N/A** (loss-making); price-to-book ~**58x**, which is very rich for a small, single-asset biotech and implies high expectations for GLSI‑100 | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Develops GLSI-100, an immunotherapy to prevent breast cancer recurrences, and if it gets approved will make money by selling the drug to oncologists/hospitals (likely via specialty distribution) at premium oncology pricing; right now it has **no product revenue** and funds itself mainly through equity capital. **Revenue Breakdown:** (currently pre‑revenue) | Business | Share | Trend | Comment | |----------|-------|-------|---------| | GLSI-100 (breast cancer recurrence prevention, Phase III FLAMINGO‑01) | N/A (no revenue yet) | ↑ | Core and basically only value driver; trial success would create the first revenue stream | | Other programs / partnerships | [Data unavailable] | → | No meaningful disclosed revenue; any secondary assets aren’t central to the thesis today | **Profitability Metrics:** (interpretation for a clinical-stage biotech) | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | [Data unavailable] | N/A | No commercial sales yet, so margins aren’t meaningful at this stage | | Net Margin | Negative | Below Average | Typical for R&D-stage biotech—spending heavily on trials with no revenue; earnings will stay negative until after approval, if any | | ROE | **-1042.8%** | Extremely weak | Signals that the equity base is small vs. cumulative losses; not unusual in small biotechs but underlines total dependence on future trial success | --- ### 📈 How’s the Growth? **Growth Assessment:** For a biotech like this, “growth” is about **pipeline progress**, not revenue. On that front: **high clinical momentum**, but **no financial growth** yet. | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | N/A | N/A | No commercial revenue; still in clinical stage | | Profit Growth | Still negative EPS (around -$0.25 to -$0.30 per quarter) | Losses roughly stable | Loss-making by design as R&D and trial costs continue | **Growth Quality (what really matters here):** - The big story is **pipeline advancement**, not near-term EPS: - Completion of **enrollment in the open-label, non‑HLA‑A*02 arm** of FLAMINGO‑01. - Screened **1,000+ patients** globally in the trial. - Reported **~80% reduction in recurrence rates** in the open-label arm by preliminary analysis. - This is **organic, “real” progress** (patients enrolled, milestones hit), not engineered by acquisitions or accounting. In other words, you’re betting on **clinical milestones turning into regulatory approval**, not on traditional revenue/EPS growth curves over the next 1–2 years. --- ### 💰 Financial Health Check **One Sentence:** Think of GLSI as someone with **no mortgage and some cash in the bank, but no salary yet and big education bills**—no debt problems today, but will need more cash unless they land a great job (drug approval or partnership). | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | **0%** | <60% safe | ✅Safe — no financial leverage risk | | Current Ratio | **2.35x** | >1.5 healthy | ✅Safe — decent short-term liquidity to cover near-term bills | | Cash Flow per Share (TTM) | **-0.48** | >0 | 🚨Negative — burning cash on R&D and trials, as expected for this stage | **So what?** - **Good news:** No debt and solid liquidity ratios mean **no immediate solvency red flag**. - **Watch out:** With negative cash flow and no revenue, **future equity raises are very likely**, which can dilute existing shareholders, especially if trial news turns less favorable. --- ### 🏷️ Is It Expensive Now? **Price Position (52-week context):** - 52-Week Low: **$7.78** - 52-Week High: **$32.91** - Current: **$22.30** → roughly **58%** of the way from low to high So it’s trading **in the middle-to-upper part** of its 52-week range—off the highs but well above the lows, consistent with a stock that’s had upbeat trial news but is still volatile. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current (~58%)** | | ● | | **Valuation Comparison:** (where we can say something) | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | PE (TTM) vs History | **N/A** | N/A | Loss-making; PE not meaningful | | Price-to-Book (P/B) | **~58x** | [Data unavailable] | Very high for a small, single-asset clinical-stage biotech | | vs Peers (small-cap biotech) | P/E N/A, P/B ~58x | Many peers at low single-digit book multiples | Suggests market is assigning a **high probability of success** to GLSI‑100 compared with typical development-stage peers | **What the Current Valuation is Betting On:** > At ~$0.3B market cap and ~58x book value, investors are implicitly betting that: > - **FLAMINGO‑01 ultimately succeeds** and leads to FDA approval/approval abroad, and > - GLSI‑100 can capture a meaningful share of the breast cancer recurrence prevention market at strong prices. > > If the Phase III data disappoints or timelines slip badly, there’s **a lot of air** that can come out of this valuation. --- ### 📰 Any Recent News? | Date (2025) | Event | Impact | |-------------|-------|--------| | Dec 29 | Extended **lock-up** of directors, officers, and pre‑IPO investors to **Sept 30, 2026** | Positive/Neutral — signals insider confidence and reduces near-term selling pressure, but also means a potential overhang when lock-up eventually ends | | Dec 22 | Corporate update on **FLAMINGO‑01** and overall strategy | Positive — reiterates Phase III focus and ongoing engagement with investors (Noble Capital conference) | | Dec 15 | Preliminary analysis shows **~80% recurrence rate reduction** in open-label non‑HLA‑A*02 arm | Positive — strong early signal; boosts optimism about GLSI‑100, though not definitive for approval | | Dec 08 | Completion of enrollment in **open-label arm** of FLAMINGO‑01 | Positive — execution milestone; keeps the trial on track for further data readouts | | Dec 03 | Global update: **>1,000 patients screened** in FLAMINGO‑01 | Positive — shows strong recruitment and global trial execution; supports eventual robust dataset | | Jan 2026 | Appeared among “Top Midday Gainers” | Neutral — reflects volatility and trader interest, often tied to news/optimism rather than fundamentals | --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data **Profitability Trends:** (annual detail not provided; high-level only) | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | N/A (no product sales) | | Net Margin | Negative | Negative | Negative | Persistent losses typical of R&D-stage biotech | | ROE | **-1042.8%** | [Data unavailable] | [Data unavailable] | Highly negative, driven by small equity base and ongoing losses | **Growth Trends:** (annualized figures not available) | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | N/A | N/A | N/A | Pre‑revenue | | Profit Growth | Still negative | Negative | Negative | No real “improvement”; losses tied to trial pace | | EPS Growth | [Data unavailable at annual level] | | | Quarterly EPS remains negative | --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter End | EPS Expected | EPS Actual | Surprise | |-------------|-------------|-----------|----------| | 2025-09-30 | -0.3009 | -0.30 | **≈0% Beat** 😀 (essentially in line) | | 2025-06-30 | -0.2448 | -0.30 | **-23% Miss** 😟 (higher loss than expected) | | 2025-03-31 | -0.2448 | -0.25 | **-2% Miss** 😟 (slight miss) | | 2024-12-31 | -0.2142 | -0.61 | **-185% Miss** 😟 (much higher loss than expected) | **Earnings Trend Interpretation:** - EPS is **consistently negative**, and the size of the loss jumps around based on **timing of R&D and trial spending**. - The huge miss in late 2024 likely reflects a **step-up in trial-related costs**, not some structural business collapse. - For this kind of company, **earnings “beats” or “misses” are far less important** than: - Cash runway - Clinical milestones - Regulatory and partnership progress --- ### III. What the Market Thinks **Analyst Ratings (most recent period):** Total covering firms: 2 (Strong Buy) + 5 (Buy) + 1 (Hold) = **8** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy / Buy | 7 | **87.5%** | | Hold | 1 | **12.5%** | | Sell / Strong Sell | 0 | 0% | Analyst stance is **clearly bullish**: most see GLSI as a **high-upside, high-risk idea** rather than something to avoid. **Target Price:** Target price range and median: **[Data unavailable]** So we can’t quantify upside vs current price from the Street’s numbers. **Insider Activity (recent months):** - Multiple transactions by **Snehal Patel** (likely a key executive/founder) with transaction code **“P”** (purchases) and one **“A”** (grant/award). - Overall, his share count has **increased** over late 2025 and early 2026 (into the 5.6M+ share range). > Interpretation: net **insider buying in share terms** (dollar value not disclosed here) usually signals **management confidence** in long-term prospects. It doesn’t guarantee success, but it’s better than insiders dumping stock ahead of key readouts. --- ### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Clinical / Regulatory Risk:** FLAMINGO‑01 is the key Phase III trial. If: - the final data fails to confirm efficacy and safety, or - regulators disagree with the trial design or results → GLSI‑100 may never reach the market, and GLSI’s equity value could **drop sharply**. 2. **Financing & Dilution Risk:** With **negative cash flow, no revenue, and no debt**, the company’s main funding tool is **new equity**: - More capital raises will likely be needed before and after key readouts. - If done at lower prices or during bad news cycles, existing shareholders can see **significant dilution**. 3. **Concentration & Volatility Risk:** - GLSI is essentially a **single-asset story**; there’s little diversification if GLSI‑100 stumbles. - Small cap (~$0.3B), **beta ~1.46**, and a hot catalyst (Phase III data) mean the stock can move **very sharply** on headlines—both up and down. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** GLSI is a small, clinical-stage biotech whose value is almost entirely tied to GLSI‑100, a Phase III immunotherapy targeting breast cancer recurrence. > > **Key strength:** It has promising preliminary clinical signals (reported ~80% recurrence reduction in an open-label arm), a debt-free balance sheet with decent liquidity, bullish analyst/insider sentiment, and insiders even extended lock-ups to 2026, suggesting confidence. > > **Key risk:** There’s no revenue, heavy cash burn, a very rich valuation for a single-asset story, and a binary dependence on FLAMINGO‑01—if the pivotal data or regulatory path disappoints, both the stock and the ability to raise capital could be hit hard. --- > **🔍 Want to Learn More?** > > • Want to know if GLSI has a durable moat if GLSI‑100 succeeds (IP, competition, pricing power)? → Try **【Buffett Mode】**. > • Want to stress-test trial, dilution, and regulatory risks in detail? → Try **【Muddy Mode】**. > • Want to think like a growth investor and model upside/downside based on approval odds and peak sales? → Try **【Musk Mode】**.